Tessellate BIO Appoints Lara Boyd as Chief Business Officer to Drive Cancer Treatment Innovation
- Dr. Lara Boyd has been appointed as Chief Business Officer at Tessellate BIO.
- Lara brings a wealth of experience from her previous roles in business development within the biotech industry.
- Her appointment is expected to enhance Tessellate BIO's efforts in creating innovative cancer treatments.
On November 4, 2024, Tessellate BIO announced the appointment of Dr. Lara Boyd as the new Chief Business Officer, adding a seasoned leader to its executive team. Previously, Lara held important roles at F-star Therapeutics and brings extensive business development experience from her time at Cancer Research Technology and Cancer Research UK. Her academic background includes a PhD from the MRC Genome Damage and Stability Centre and post-doctoral research at the Barts Cancer Institute. Lara Boyd expressed her excitement about joining Tessellate BIO, highlighting the company’s focus on developing novel cancer treatments that meet the needs of patients. With her extensive background in cancer research and business strategy, she is expected to significantly contribute to the company’s growth and vision. Tessellate BIO is dedicated to innovative approaches in the oncology sector, particularly through its focus on Synthetic Lethality. The company aims to create new therapies and diagnostics to help identify and treat ALT positive cancers, enhancing the precision of patient care. The leadership of Andree Blaukat, CEO, emphasizes the intention to leverage Lara's expertise to bolster their ongoing development efforts. Headquartered in the Netherlands, and now strengthened by Lara's appointment, Tessellate BIO aims to drive advancements in cancer treatment while addressing the urgent needs of patients who currently lack effective options.